Table 4.
Mean Change for Q-LES-Q SF percentage maximum scores from baseline to 6 weeks: adjunctive therapy (Lurasidone 20–120 mg/day and Placebo)
| Lurasidone 20–120 mg/day | Placebo | |||||
|---|---|---|---|---|---|---|
| N Mean (SD) | N Mean Change (SD) | P value | N Mean (SD) | N Mean Change (SD) | P value | |
| Q-LES-Q SF | ||||||
| Baseline | 177 36.1 (14.3) | -- | 159 35.7 (13.5) | -- | ||
| 6-Weeks | 142 58.4 (181) | 141 23.3 (18.7) | <.0001 | 135 52.7 (19.9) | 134 17.9 (20.2) | <.0001 |
All p-values for Q-LES-Q SF outcomes are based on t-tests comparing differences from baseline to 6 weeks within treatment group